Multiple myeloma is a malignancy of terminally differentiated plasma cells, and patients typically present with bone marrow infiltration of clonal plasma cells and monoclonal protein in the serum and/or urine. The diagnosis of multiple myeloma is made when clear end-organ damage attributable to the plasma cell proliferative disorder or when findings that suggest a high likelihood of their development are present. Distinguishing symptomatic multiple myeloma that requires treatment from the precursor stages of monoclonal gammopathy of undetermined significance and smouldering multiple myeloma is important, as observation is the standard for those conditions. Much progress has been made over the past decade in the understanding of disease biology and individualized treatment approaches. Several new classes of drugs, such as proteasome inhibitors and immunomodulatory drugs, have joined the traditional armamentarium (corticosteroids, alkylating agents and anthracyclines) and, along with high-dose therapy and autologous haemopoietic stem cell transplantation, have led to deeper and durable clinical responses. Indeed, an increasing proportion of patients are achieving lasting remissions, raising the possibility of cure for this disease. Success will probably depend on using combinations of effective agents and treating patients in the early stages of disease, such as patients with smouldering multiple myeloma.

Multiple myeloma

Gay F.;
2017-01-01

Abstract

Multiple myeloma is a malignancy of terminally differentiated plasma cells, and patients typically present with bone marrow infiltration of clonal plasma cells and monoclonal protein in the serum and/or urine. The diagnosis of multiple myeloma is made when clear end-organ damage attributable to the plasma cell proliferative disorder or when findings that suggest a high likelihood of their development are present. Distinguishing symptomatic multiple myeloma that requires treatment from the precursor stages of monoclonal gammopathy of undetermined significance and smouldering multiple myeloma is important, as observation is the standard for those conditions. Much progress has been made over the past decade in the understanding of disease biology and individualized treatment approaches. Several new classes of drugs, such as proteasome inhibitors and immunomodulatory drugs, have joined the traditional armamentarium (corticosteroids, alkylating agents and anthracyclines) and, along with high-dose therapy and autologous haemopoietic stem cell transplantation, have led to deeper and durable clinical responses. Indeed, an increasing proportion of patients are achieving lasting remissions, raising the possibility of cure for this disease. Success will probably depend on using combinations of effective agents and treating patients in the early stages of disease, such as patients with smouldering multiple myeloma.
2017
3
1
17046-01
17046-20
http://www.nature.com/nrdp/
https://www.nature.com/articles/nrdp201746
Bone Marrow; Epigenomics; Hematopoietic Stem Cell Transplantation; Humans; Immunomodulation; Incidence; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Myeloma Proteins; Paraproteinemias; Plasma Cells; Prevalence; Proteasome Inhibitors; Risk Factors; Transplantation, Autologous; Tumor Microenvironment; United States
Kumar S.K.; Rajkumar V.; Kyle R.A.; Van Duin M.; Sonneveld P.; Mateos M.-V.; Gay F.; Anderson K.C.
File in questo prodotto:
File Dimensione Formato  
[Publisher Version] Kumar et al - 2017 - Multiple Myeloma - nrdp201746.pdf

Accesso riservato

Descrizione: [Publisher Version] Kumar et al - 2017 - Multiple Myeloma - nrdp201746
Tipo di file: PDF EDITORIALE
Dimensione 1.31 MB
Formato Adobe PDF
1.31 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1732800
Citazioni
  • ???jsp.display-item.citation.pmc??? 295
  • Scopus 770
  • ???jsp.display-item.citation.isi??? 483
social impact